$469 Million is the total value of BVF INC/IL's 34 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 250.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $58,629,000 | +23.0% | 2,895,251 | +9.7% | 12.49% | +5.9% |
| CYTK | Buy | CYTOKINETICS INC | $47,348,000 | +54.7% | 4,989,218 | +14.9% | 10.09% | +33.2% |
| ARRY | Buy | ARRAY BIOPHARMA INC | $29,409,000 | +27.0% | 8,260,897 | +5.2% | 6.26% | +9.3% |
| IONS | New | IONIS PHARMACEUTICALS INC | $19,797,000 | – | 850,000 | +100.0% | 4.22% | – |
| GLYC | New | GLYCOMIMETICS INC | $17,793,000 | – | 2,447,415 | +100.0% | 3.79% | – |
| CASC | New | CASCADIAN THERAPEUTICS INC | $17,730,000 | – | 18,799,368 | +100.0% | 3.78% | – |
| NVLS | Buy | NIVALIS THERAPEUTICS INC | $8,862,000 | +37.4% | 1,926,443 | +24.5% | 1.89% | +18.3% |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $7,998,000 | – | 575,000 | +100.0% | 1.70% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $6,896,000 | – | 5,184,600 | +100.0% | 1.47% | – |
| ADRO | New | ADURO BIOTECH INC | $5,809,000 | – | 513,603 | +100.0% | 1.24% | – |
| MGNX | New | MACROGENICS INC | $5,398,000 | – | 200,000 | +100.0% | 1.15% | – |
| OREX | New | OREXIGEN THERAPEUTICS INC | $2,258,000 | – | 5,252,100 | +100.0% | 0.48% | – |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $389,000 | – | 241,352 | +100.0% | 0.08% | – |
| AVIR | New | AVIRAGEN THERAPEUTICS INC | $292,000 | – | 208,353 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.